S1PR1 and myeloid sarcoma: Since certain subtypes of Multiple sclerosis (MS)—another immunological/inflammatory disease of the brain—can be treated since 2011 quite successfully with the sphingosine-1-phosphate receptor modulator Fingolimod (FTY720, Gilenya), it seems reasonable to study its effects in other neurodegenerative diseases that involve inflammation.